Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP3 | P08254 | 4/20 | 0.48 |
| ▸ | MMP7 | P09237 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | CTSE | P14091 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 4/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194766 | 1.00 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ASTSGPR119 | |
| SCHEMBL31510737 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ASTSGPR119 | |
| SCHEMBL16874620 | 0.88 | KDM1A (0.50) | ALDH1A1MEN1KMT2ASTSGPR119 | |
| SCHEMBL16874622 | 0.88 | KDM1A (0.50) | ALDH1A1MEN1KMT2ASTSGPR119 | |
| SCHEMBL4602756 | 0.88 | PDE4B (0.46) | ALDH1A1KMT2ASTSGPR119PDE4B | |
| SCHEMBL3062563 | 0.88 | PDE4B (0.46) | ALDH1A1KMT2ASTSGPR119PDE4B | |
| SCHEMBL26808070 | 0.88 | GPR119 (0.55) | KMT2AGPR119PDE4BMMP13 | |
| SCHEMBL16874803 | 0.88 | PDE4B (0.46) | ALDH1A1KMT2ASTSGPR119PDE4B | |
| SCHEMBL24244951 | 0.87 | PDE4B (0.46) | ALDH1A1KMT2AGPR119PDE4B | |
| SCHEMBL3069366 | 0.87 | PDE4B (0.46) | ALDH1A1KMT2AGPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3092224-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180000807-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170258777-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3092224-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885MEN1 2817/4885KMT2A 3839/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885MEN1 2817/4885KMT2A 3839/4885 |
| US-20180000807-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20170258777-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20160081995-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | ALDH1A1 2090/4885MEN1 4538/4885KMT2A 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.